Become a member
Home
COSSF

COSSF

The Strategic and Scientific Steering Committee of the Sector (COSSF) is MabDesign’s scientific body. It is made up of 18 permanent experts:

Alain Beck

PIERRE FABRE

Director of the CIPF Antibody Physico-Chemistry Department and associate editor of the scientific journal mAbs

Paul Baduel

SANOFI

Director Manufacturing Technology International Sites, SANOFI Pasteur

Jean-Louis Pinquier

DECISIONS R&D Consulting

Doctor, Chairman of the Translational Medicine Strategic Committee at MEDICEN, Consultant at DECISIONS R&D consulting

Jean-François Prost

JFP Consulting

Consultant in Medical and Scientific Affairs

Jérôme Tiollier

OUR FUTURE UNIVERSE

President and Co-Founder, Our Future Universe

Bernard Vanhove

BV Bioconsult

Président, BV Consult

Hervé Watier

MABIMPROVE

Professor of immunology at the Faculty of Medicine of Tours, Head of the immunology department at the University Hospital of Tours

Nicolas Poirier

TIKEOBIO

Chairman & Founder

Aurore Morello

OSE IMMUNOTHERAPEUTICS

Directrice Scientifique

Stéphanie Cornen

INNATE PHARMA

Vice-présidente, Relations Investisseurs, Communication et Stratégie Commerciale

Thierry Wurch

Fair Journey Biologics

Senior VP Late-Stage Development

Nathalie Corvaïa

NCO Biotech Consulting

CEO

Hubert Méchain

Établissement Français du Sang (EFS)

Directeur National Bioproduction/MTI

Direction Générale Chaîne Transfusionnelle, Thérapies et Developpements

Félix A. Montero Julian

BIOMÉRIEUX

Scientific Director, Business Healthcare, Industry Unit

Gregory Batt

INRIA / INSTITUT PASTEUR

Senior Researcher, Head of InBio Research Group

Oumeya (Mia ) Adjali

Université de Nantes / INSERM

Senior Scientist in Gene Therapy, Head of TaRGeT laboratory

Hervé Broly

ex- Merck Serono

ex-VP Biotech Process Development.
Expert CMC

Hélène NEGRE

CELLforCURE by Seqens

Responsible Pharmacist and Pharmaceutical Affairs Director

Nicolas SALAVIN

SANOFI

Head of Strategy, External Innovation & Performance – Centre d’Excellence mRNA

JEAN-ROCH FABREGUETTES

Centre MEARY AP-HP

Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis

Its missions are as follows:

  • Define and decide on the scientific orientations of MabDesign, in particular on the themes of animation and continuing education.
  • Write forward-looking reports on concrete topics in the sector twice a year.

Alain Beck

PIERRE FABRE

Senior Director Biologics CMC & Developability du CIPF & mAbs Jornal Associated Editor

Dr. Alain Beck is Senior Director, Biologics CMC and Developability at Pierre Fabre, co-founder and associate editor of mAbs (2009), and Chairman of the COSSF at MabDesign (2014). He is or has been involved in more than 10 clinical-stage biologics R&D programs, including dalotuzumab (Merck), telisotuzumab/telisotuzumab vedotin (AbbVie), the ADC ugodotin de lonigutamab and W0180 Vista mAb (PF), the Fc fusion protein ER004 (www.esperare.org) and VB421/lonigutamab (www.valenzabiotech.com). He is the author/co-author of over 250 publications (h-index: 60; over 14,000 citations). He has contributed to over 280 scientific conferences (AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chair, guest speaker, panelist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, Bs/MsAbs, Fc-fusions, Immunocytokines, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6th out of 50 influential people in the global antibody industry (2013) and was the 6th WADC (2019) and 10th AIS Award winner (2022) for his long and outstanding contribution in these fields. He is a member of the MAB working group (EDQM/PhEur) and participates in workshops with ANSM, the EU, EMA, FDA, NIST, USP, and WHO.

Paul Baduel

SANOFI

Director Manufacturing Technology International Sites, Sanofi

Paul Baduel graduated in biochemical engineering from INSA Toulouse in 1986. He began his career in 1988 in the molecular biology division of Rhône Poulenc Santé’s research department in Vitry-sur-Seine, where he was responsible for developing fermentation processes for the production of therapeutic proteins.

In the 1990s, he was responsible for developing manufacturing processes for new antibiotics and contributed to the industrialization of a new recombinant process for the production of vitamin B12. He then served as project manager for the development of new antibiotics obtained through semi-synthesis. He then took charge of Rhône Poulenc Rorer’s biotechnology department, responsible for industrialization and industrial production support.

From 2000 to 2012, Paul Baduel headed up the biotechnology departments at Aventis, then Sanofi, in Germany, Italy, and France. In these roles, he contributed to the industrialization and development of insulins at the Frankfurt site and to the conversion of the Vitry-sur-Seine site for the development and industrial production of monoclonal antibodies.

Since 2013, Paul Baduel has been responsible for global technological innovation at Sanofi-Pasteur and the vaccine division of the Sanofi group. He is currently International Director of Production Technology at Sanofi-Pasteur.

Jean-Louis Pinquier

DECISIONS R&D Consulting

Doctor, Chairman of the Translational Medicine Strategic Committee at MEDICEN, Consultant at DECISIONS R&D consulting

Jean-Louis Pinquier, MD, is currently the chair of the Strategic Committee for Translational Medicine at MEDICEN, and also serves as a consultant at DECISIONS R&D consulting. Over the past 30 years, he has participated in more than a hundred drug candidate development programs, from the research stage to registration and beyond. He has been particularly active in early clinical development, covering a very wide range of therapeutic areas. Since the early 2000s, he has been involved in several programs for the development of therapeutic biological molecules, including naked and conjugated monoclonal antibodies. Until 2014, he was Global Deputy Director of the Clinical and Exploratory Pharmacology Department at Sanofi R&D and a member of the Sanofi R&D France Management Committee. After spending seven years at Cochin University Hospital as Assistant Head of Clinic, then as Medical Director of the Institute for Therapeutic Research, he joined the pharmaceutical industry in 1993, first at Syntheabo Recherche, then at Sanofi-Synthelabo Recherche, Aventis, and finally Sanofi-Aventis.

Jean-Louis Pinquier is a clinical pharmacologist, internist, and rheumatologist who continues to practice medicine in hospitals. He is a member of the ASCPT, ACCP, SFTP, Club Phase 1 (of which he is the current president), and EUFEMED.

Jean-François Prost

JFP Consulting

Consultant in Medical and Scientific Affaires

Jean-François Prost is a Senior Consultant in the French and international pharmaceutical industry. A doctor specializing in general medicine, Jean-François Prost has 30 years of experience in the industry. He worked at Laboratoires Servier as Director of Cardiovascular Development, then as Director of Research at Pierre Fabre Médicaments and at UCB Pharma as Director of Research and Development. For the past 10 years, he has been Scientific and Medical Director at LFB. He was Vice President of R&D and Strategy at GamaMabs Pharma. He is now a Consultant in Medical and Scientific Affairs.

Jérôme Tiollier

OUR FUTURE UNIVERSE

Président, Co-Founder, Our Future Universe

Jérôme TIOLLIER PhD, has worked for 35 years in various executive positions in the pharmaceutical and biotech industry in France. He has managed and supervised multiple aspects of drug development, including CMC, non-clinical development, toxicology, PK, translational research, clinical and regulatory operations, and phase I/II trials.

Responsible for all operational aspects of projects, timelines, resources, and budgets, enabling the achievement of corporate objectives in the dynamic growth environment of companies in the sector. He participated in the development and implementation of strategies as part of the Executive Committee. With a PhD in Cell Biology and Immunology, he developed his skills in the field of pharmaceutical development of “first-in-class” candidates and led a dozen new products from concept to clinical development in various medical fields: wound healing, surgical implants, transplantation, and oncology.

He was EVP CDO at INNATE PHARMA (2001-2018), a member of the Executive Committee, and participated in the company’s strategic and corporate development, its successive fundraisings, its IPO (2006), its development to a peak market capitalization of $1 billion, and most recently, the acquisition of a product enabling Innate to become a FIPCO. During this period, in 2008, he launched US operations by creating IPH Inc., which will be used in 2019 to create the commercial network.

Previously, he worked at Pasteur-Mérieux Transplant business unit (acquired by SANGSTAT in 1998) from 1997 to 2001 and began his career at IMEDEX (a spin-off of the Institut Mérieux group) in various positions from 1987 to 1996.

In early 2019, Jerome Tiollier teamed up with several media and communications managers to launch Our Future Universe, a new digital media platform providing scientific, clinical, and business information in various fields of biomedicine, with the aim of becoming the new encyclopedia of the field.

Bernard Vanhove

BV Consult

President, BV Consult

Dr. Bernard Vanhove is an accomplished researcher with over 20 years of experience in immunology, focusing on transplant immunology, autoimmunity, and immuno-oncology. He has authored more than 125 peer-reviewed articles in these fields and is a recipient of the France Transplant Prize.
He serves as a CNRS Director of Research in Pharmacology and Biomedical Engineering. Dr. Vanhove was the former leader of the FP6 European network TRIAD (T Cell Regulation in Autoimmune Disease). He is also the founder and former CEO of the biotech company Effimune, and has held leadership positions as COO of Ose Immunotherapeutics and COO/CSO of Xenothera.
Dr. Vanhove holds a PhD in Immunology from the University of Louvain in Belgium and completed post-doctoral studies in molecular biology at the Sandoz International Research Collaboration Centre in Vienna, Austria. He also has a degree in Business Administration from Audencia Business School in Nantes, France. He is now President of BV Consult consulting company.

Hervé Watier

MABIMPROVE

Professor of immunology at the Faculty of Medicine of Tours, Head of the immunology department at the University Hospital of Tours

Hervé Watier is a professor of immunology at the Faculty of Medicine in Tours and head of the immunology department at the Tours University Hospital. As a physician and scientist, he works on the mechanisms of action of therapeutic antibodies in humans, which he helped discover through pharmacogenetic approaches. He has headed the CNRS 3260 research group “Antibodies and Therapeutic Targeting” since 2009, coordinated the ‘MAbImprove’ laboratory of excellence (LabEx) since 2011, and led the ARD 2020 “Biomedicines” program in the Centre-Val de Loire region since 2013.

Nicolas Poirier

TikeBio

Founder, TikeBio

Nicolas Poirier brings over 20 years at the intersection of immunology, immunotherapy R&D, and pharma business development, including a decade as CSO, then CEO, and Board member of a publicly listed biotech. He has a strong track record of translating breakthrough immunology science into clinical-stage programs and landmark pharma partnerships. He has built first-in-class pipelines, leading immunotherapy programs from target discovery and antibody engineering through IND-enabling studies to Phase 1 and Phase 2 proof-of-efficacy trials in oncology, immuno-inflammation, and transplantation. As CEO and CSO of OSE Immunotherapeutics (Euronext: OSE), he signed six pharma partnerships with AbbVie, Janssen, Boehringer Ingelheim, Servier, and Veloxis, totaling over €2.5B. He is also the author of 50+ publications and inventor on 60 patent families spanning immunotherapy, biomarkers, antibody, peptide, and RNA therapeutic engineering.

Aurore Morello

OSE IMMUNOTHERAPEUTICS

Chief Scientific Officer, OSE Immunotherapeutics

Aurore Morello holds a PhD in Immunology from the University of Bordeaux and completed her postdoctoral training at Memorial Sloan Kettering Cancer Center in New York. She has been with OSE Immunotherapeutics for more than ten years and currently serves as Chief Scientific Officer. Her expertise covers the development of innovative therapies in oncology and inflammatory diseases, with a particular focus on monoclonal and bispecific antibodies, immunocytokines, and therapeutic RNA.

 

Stéphanie Cornen

INNATE PHARMA

Vice President, Investor Relations, Communication & Commercial Strategy, Innate Pharma

Stéphanie Cornen joined Innate Pharma in May 2012 as a research and development manager in the Antibodies department. She became a project manager in 2014, working on the discovery of new blocking antibodies. Since 2016, she has been leading the new target discovery program, which aims to identify and validate new therapeutic targets in immuno-oncology. Ms. Cornen holds a PhD in Pharmacy and a PhD in Oncology (Aix-Marseille University).

Thierry Wurch

Fair Journey Biologics

Senior Vice-President Late-Stage Development

Nathalie Corvaïa

NCO Biotech Consulting

CEO

Sophie Derenne

ÉTABL. FRANÇAIS DU SANG

Head of Dep. Analysis and Dev. of Markets, Department of Biology, Therapies and Diagnostics, EFS

Sophie DERENNE is a biologist pharmacist and holds a PhD in Life Sciences (University of Nantes). She began her career in Biological Hematology at Nantes University Hospital and then joined the French Blood Establishment in 2005, notably as head of the Cell Therapy Unit from 2009 onwards.

She has been involved in the production of Advanced Therapy Medicinal Products (ATMPs) in cell and gene therapy since the opening of EFS Atlantic Bio GMP in 2010, successively holding the positions of Quality Manager, Interim Pharmacist Manager of EFS, and Manager of the ATMP platform. During these years, she took charge of the regulatory and pharmaceutical aspects associated with ITMs and was particularly involved in the development of ITM projects, working closely with project leaders to facilitate access to clinical trials.

Involved in a Cell Therapy and MTI project at the headquarters of the French Blood Establishment (EFS) at the end of 2019, she joined the Biology, Therapies, and Diagnostics Department in March 2021 as Head of the Analysis and Market Development Department.

Félix A. Montero Julian

BIOMÉRIEUX

Directeur Scientifique, Business Healthcare, Unité Industrie

Felix A. MONTERO JULIAN PhD a plus de 30 ans d’expérience en industrie pharmaceutique, diagnostique clinique et sciences de la vie et il a été notamment Directeur du département Analyse Cellulaire chez Beckman Coulter et par la suite Directeur du site d’Ivry sur Seine et de la R&D de la gamme des produits CHEMUNEX. Il est diplômé de l’Université Autonome Métropolitaine [UAM] à Mexico comme Ingénieur en Biochimie Industrielle et a obtenu un Doctorat en Sciences avec une spécialité en Immunologie à l’université d ’Aix-Marseille Luminy.

Il est membre de plusieurs organisations telles que la PDA, ISAC, ISCT, A3P, et expert en méthodes rapides de microbiologie, il a contribué à la création du chapitre USP <1071> RAPID MICROBIAL TESTS FOR RELEASE OF STERILE SHORT-LIFE PRODUCTS: A RISK-BASED APPROACH. Il est toujours actif dans la promotion et l’acceptation de ces méthodes. Il est un conférencier de premier plan dans différents congrès et une contributeur régulier à la communication scientifique de BioMérieux. Il s’intéresse au technologies et méthodes analytiques de control des produits de thérapie cellulaire et génique et de processus de bioproduction.

Gregory Batt

INRIA / INSTITUT PASTEUR

Senior Researcher, Head of InBio Research Group

Gregory Batt is a senior research scientist at Inria and the head of the InBio group at Institut Pasteur.

Dr Batt studied molecular and cellular biology and computer science at the Ecole Normale Supérieure de Lyon. He received his PhD in computer science from the University of Grenoble in 2006. Prior to joining Inria in 2007, he was a postdoctoral researcher at Boston University. Since 2017, he leads the InBio team, an Inria/Institut Pasteur research group.

The InBio team is interested in understanding, controlling and optimizing cellular processes from the single cell to the cell population levels.
InBio members combine wet and dry biology in the same lab. They employ systems and synthetic biology approaches with control and active learning methods, together with stochastic and statistical modeling frameworks.
They also develop affordable bioreactor-based platforms with automated measurements and reactive experiment control.
In recent applications, they have designed an artificial differentiation system in yeast and used it to create consortia with tuneable composition, and have characterized protein secretion under various stress conditions to optimize production in yeast.

Oumeya (Mia ) Adjali

Université de Nantes / INSERM

Senior Scientist in Gene Therapy, Head of TaRGeT laboratory

Hervé Broly

ex-MERCK Serono

ex-VP Biotech Process Development.
Expert CMC

Hélène Negre

CELLforCURE by Seqens

Responsible Pharmacist and Pharmaceutical Affairs Director

Nicolas Salavin

SANOFI

Head of Strategy, External Innovation & Performance – Centre d’Excellence mRNA, Sanofi

Nicolas Salavin has over twenty years of experience in biotechnology and bioproduction at the intersection of science, industry, and strategy. He has built his career with major players in the sector such as Sanofi, Total/Amyris, and ABL (Institut Mérieux/Oxford Biomedica).

A graduate of AgroParisTech in molecular biology and modeling, and holder of a ParisTech Master’s degree in process engineering, he has developed comprehensive expertise covering the main biopharmaceutical technology platforms and several products.

Throughout his career, Nicolas has supported the transformation of the biopharmaceutical sector through roles with significant technical, operational, and strategic responsibility.

Today, at Sanofi’s mRNA Center of Excellence, Nicolas Salavin oversees strategy, external innovation, and portfolio management.

Jean-Roch Fabreguettes

MEARY

Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris

Jean-Roch Fabreguettes est un spécialiste de la recherche translationnelle et des phases précoces de développement clinique des médicaments de thérapie innovantes (MTI). Pharmacien, titulaire d’un doctorat de l’Université de Montpellier 1, il a travaillé plus de 25 ans dans le domaine et a contribué, pour des équipes académiques comme pour des start-ups, à la réalisation de plus de 30 programmes de recherche sur différents types de MTI : thérapie génique in vivo ou ex vivo, thérapie cellulaire, ingénierie tissulaire… Il est actuellement Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris. Le centre MEARY est une plateforme de l’Assistance Publique – Hôpitaux de Paris (AP-HP), dédiée à la fabrication de médicament de thérapie innovante expérimentaux. Laboratoire membre de l’ISCT, il est autorisé par l’ANSM et dispose d’un certificat GMP. A ce titre Jean-Roch Fabreguettes est impliqué dans le développement clinique et la fabrication de nombreux MTI : CAR-T cells, lymphocytes T régulateurs, cellules stromales mésenchymateuses…

Précédemment, Jean-Roch Fabreguettes a été expert Qualité (CMC) auprès de l’ANSM durant 9 ans et a conseillé différentes sociétés de biotechnologies. Il est un intervenant régulier pour l’Université Paris Cité et un membre actif de l’ISCT et de réseaux nationaux et internationaux sur les MTI (UNI-TC, Join4ATMP).

Alain Beck

PIERRE FABRE

Senior Director Biologics CMC & Developability du CIPF & mAbs Jornal Associated Editor

Dr. Alain Beck is Senior Director, Biologics CMC and Developability at Pierre Fabre, co-founder and associate editor of mAbs (2009), and Chairman of the COSSF at MabDesign (2014). He is or has been involved in more than 10 clinical-stage biologics R&D programs, including dalotuzumab (Merck), telisotuzumab/telisotuzumab vedotin (AbbVie), the ADC ugodotin de lonigutamab and W0180 Vista mAb (PF), the Fc fusion protein ER004 (www.esperare.org) and VB421/lonigutamab (www.valenzabiotech.com). He is the author/co-author of over 250 publications (h-index: 60; over 14,000 citations). He has contributed to over 280 scientific conferences (AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chair, guest speaker, panelist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, Bs/MsAbs, Fc-fusions, Immunocytokines, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6th out of 50 influential people in the global antibody industry (2013) and was the 6th WADC (2019) and 10th AIS Award winner (2022) for his long and outstanding contribution in these fields. He is a member of the MAB working group (EDQM/PhEur) and participates in workshops with ANSM, the EU, EMA, FDA, NIST, USP, and WHO.

Paul Baduel

SANOFI

Director Manufacturing Technology International Sites, Sanofi

Paul Baduel graduated in biochemical engineering from INSA Toulouse in 1986. He began his career in 1988 in the molecular biology division of Rhône Poulenc Santé’s research department in Vitry-sur-Seine, where he was responsible for developing fermentation processes for the production of therapeutic proteins.

In the 1990s, he was responsible for developing manufacturing processes for new antibiotics and contributed to the industrialization of a new recombinant process for the production of vitamin B12. He then served as project manager for the development of new antibiotics obtained through semi-synthesis. He then took charge of Rhône Poulenc Rorer’s biotechnology department, responsible for industrialization and industrial production support.

From 2000 to 2012, Paul Baduel headed up the biotechnology departments at Aventis, then Sanofi, in Germany, Italy, and France. In these roles, he contributed to the industrialization and development of insulins at the Frankfurt site and to the conversion of the Vitry-sur-Seine site for the development and industrial production of monoclonal antibodies.

Since 2013, Paul Baduel has been responsible for global technological innovation at Sanofi-Pasteur and the vaccine division of the Sanofi group. He is currently International Director of Production Technology at Sanofi-Pasteur.

Jean-Louis Pinquier

DECISIONS R&D Consulting

Doctor, Chairman of the Translational Medicine Strategic Committee at MEDICEN, Consultant at DECISIONS R&D consulting

Jean-Louis Pinquier, MD, is currently the chair of the Strategic Committee for Translational Medicine at MEDICEN, and also serves as a consultant at DECISIONS R&D consulting. Over the past 30 years, he has participated in more than a hundred drug candidate development programs, from the research stage to registration and beyond. He has been particularly active in early clinical development, covering a very wide range of therapeutic areas. Since the early 2000s, he has been involved in several programs for the development of therapeutic biological molecules, including naked and conjugated monoclonal antibodies. Until 2014, he was Global Deputy Director of the Clinical and Exploratory Pharmacology Department at Sanofi R&D and a member of the Sanofi R&D France Management Committee. After spending seven years at Cochin University Hospital as Assistant Head of Clinic, then as Medical Director of the Institute for Therapeutic Research, he joined the pharmaceutical industry in 1993, first at Syntheabo Recherche, then at Sanofi-Synthelabo Recherche, Aventis, and finally Sanofi-Aventis.

Jean-Louis Pinquier is a clinical pharmacologist, internist, and rheumatologist who continues to practice medicine in hospitals. He is a member of the ASCPT, ACCP, SFTP, Club Phase 1 (of which he is the current president), and EUFEMED.

Jean-François Prost

JFP Consulting

Consultant in Medical and Scientific Affaires

Jean-François Prost is a Senior Consultant in the French and international pharmaceutical industry. A doctor specializing in general medicine, Jean-François Prost has 30 years of experience in the industry. He worked at Laboratoires Servier as Director of Cardiovascular Development, then as Director of Research at Pierre Fabre Médicaments and at UCB Pharma as Director of Research and Development. For the past 10 years, he has been Scientific and Medical Director at LFB. He was Vice President of R&D and Strategy at GamaMabs Pharma. He is now a Consultant in Medical and Scientific Affairs.

Jérôme Tiollier

OUR FUTURE UNIVERSE

Président, Co-Founder, Our Future Universe

Jérôme TIOLLIER PhD, has worked for 35 years in various executive positions in the pharmaceutical and biotech industry in France. He has managed and supervised multiple aspects of drug development, including CMC, non-clinical development, toxicology, PK, translational research, clinical and regulatory operations, and phase I/II trials.

Responsible for all operational aspects of projects, timelines, resources, and budgets, enabling the achievement of corporate objectives in the dynamic growth environment of companies in the sector. He participated in the development and implementation of strategies as part of the Executive Committee. With a PhD in Cell Biology and Immunology, he developed his skills in the field of pharmaceutical development of “first-in-class” candidates and led a dozen new products from concept to clinical development in various medical fields: wound healing, surgical implants, transplantation, and oncology.

He was EVP CDO at INNATE PHARMA (2001-2018), a member of the Executive Committee, and participated in the company’s strategic and corporate development, its successive fundraisings, its IPO (2006), its development to a peak market capitalization of $1 billion, and most recently, the acquisition of a product enabling Innate to become a FIPCO. During this period, in 2008, he launched US operations by creating IPH Inc., which will be used in 2019 to create the commercial network.

Previously, he worked at Pasteur-Mérieux Transplant business unit (acquired by SANGSTAT in 1998) from 1997 to 2001 and began his career at IMEDEX (a spin-off of the Institut Mérieux group) in various positions from 1987 to 1996.

In early 2019, Jerome Tiollier teamed up with several media and communications managers to launch Our Future Universe, a new digital media platform providing scientific, clinical, and business information in various fields of biomedicine, with the aim of becoming the new encyclopedia of the field.

Bernard Vanhove

BV Consult

President, BV Consult

Dr. Bernard Vanhove is an accomplished researcher with over 20 years of experience in immunology, focusing on transplant immunology, autoimmunity, and immuno-oncology. He has authored more than 125 peer-reviewed articles in these fields and is a recipient of the France Transplant Prize.
He serves as a CNRS Director of Research in Pharmacology and Biomedical Engineering. Dr. Vanhove was the former leader of the FP6 European network TRIAD (T Cell Regulation in Autoimmune Disease). He is also the founder and former CEO of the biotech company Effimune, and has held leadership positions as COO of Ose Immunotherapeutics and COO/CSO of Xenothera.
Dr. Vanhove holds a PhD in Immunology from the University of Louvain in Belgium and completed post-doctoral studies in molecular biology at the Sandoz International Research Collaboration Centre in Vienna, Austria. He also has a degree in Business Administration from Audencia Business School in Nantes, France. He is now President of BV Consult consulting company.

Hervé Watier

MABIMPROVE

Professor of immunology at the Faculty of Medicine of Tours, Head of the immunology department at the University Hospital of Tours

Hervé Watier is a professor of immunology at the Faculty of Medicine in Tours and head of the immunology department at the Tours University Hospital. As a physician and scientist, he works on the mechanisms of action of therapeutic antibodies in humans, which he helped discover through pharmacogenetic approaches. He has headed the CNRS 3260 research group “Antibodies and Therapeutic Targeting” since 2009, coordinated the ‘MAbImprove’ laboratory of excellence (LabEx) since 2011, and led the ARD 2020 “Biomedicines” program in the Centre-Val de Loire region since 2013.

Nicolas Poirier

TikeBio

Founder, TikeBio

Nicolas Poirier brings over 20 years at the intersection of immunology, immunotherapy R&D, and pharma business development, including a decade as CSO, then CEO, and Board member of a publicly listed biotech. He has a strong track record of translating breakthrough immunology science into clinical-stage programs and landmark pharma partnerships. He has built first-in-class pipelines, leading immunotherapy programs from target discovery and antibody engineering through IND-enabling studies to Phase 1 and Phase 2 proof-of-efficacy trials in oncology, immuno-inflammation, and transplantation. As CEO and CSO of OSE Immunotherapeutics (Euronext: OSE), he signed six pharma partnerships with AbbVie, Janssen, Boehringer Ingelheim, Servier, and Veloxis, totaling over €2.5B. He is also the author of 50+ publications and inventor on 60 patent families spanning immunotherapy, biomarkers, antibody, peptide, and RNA therapeutic engineering.

Stéphanie Cornen

INNATE PHARMA

Vice President, Investor Relations, Communication & Commercial Strategy, Innate Pharma

Stéphanie Cornen joined Innate Pharma in May 2012 as a research and development manager in the Antibodies department. She became a project manager in 2014, working on the discovery of new blocking antibodies. Since 2016, she has been leading the new target discovery program, which aims to identify and validate new therapeutic targets in immuno-oncology. Ms. Cornen holds a PhD in Pharmacy and a PhD in Oncology (Aix-Marseille University).

Sophie Derenne

ÉTABL. FRANÇAIS DU SANG

Head of Dep. Analysis and Dev. of Markets, Department of Biology, Therapies and Diagnostics, EFS

Sophie DERENNE is a biologist pharmacist and holds a PhD in Life Sciences (University of Nantes). She began her career in Biological Hematology at Nantes University Hospital and then joined the French Blood Establishment in 2005, notably as head of the Cell Therapy Unit from 2009 onwards.

She has been involved in the production of Advanced Therapy Medicinal Products (ATMPs) in cell and gene therapy since the opening of EFS Atlantic Bio GMP in 2010, successively holding the positions of Quality Manager, Interim Pharmacist Manager of EFS, and Manager of the ATMP platform. During these years, she took charge of the regulatory and pharmaceutical aspects associated with ITMs and was particularly involved in the development of ITM projects, working closely with project leaders to facilitate access to clinical trials.

Involved in a Cell Therapy and MTI project at the headquarters of the French Blood Establishment (EFS) at the end of 2019, she joined the Biology, Therapies, and Diagnostics Department in March 2021 as Head of the Analysis and Market Development Department.

Hervé Broly

ex-MERCK Serono

ex-VP Biotech Process Development.
Expert CMC

Hélène Negre

CELLforCURE by Seqens

Responsible Pharmacist and Pharmaceutical Affairs Director

Nicolas Salavin

SANOFI

Head of Strategy, External Innovation & Performance – Centre d’Excellence mRNA, Sanofi

Nicolas Salavin has over twenty years of experience in biotechnology and bioproduction at the intersection of science, industry, and strategy. He has built his career with major players in the sector such as Sanofi, Total/Amyris, and ABL (Institut Mérieux/Oxford Biomedica).

A graduate of AgroParisTech in molecular biology and modeling, and holder of a ParisTech Master’s degree in process engineering, he has developed comprehensive expertise covering the main biopharmaceutical technology platforms and several products.

Throughout his career, Nicolas has supported the transformation of the biopharmaceutical sector through roles with significant technical, operational, and strategic responsibility.

Today, at Sanofi’s mRNA Center of Excellence, Nicolas Salavin oversees strategy, external innovation, and portfolio management.

Jean-Roch Fabreguettes

MEARY

Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris

Jean-Roch Fabreguettes est un spécialiste de la recherche translationnelle et des phases précoces de développement clinique des médicaments de thérapie innovantes (MTI). Pharmacien, titulaire d’un doctorat de l’Université de Montpellier 1, il a travaillé plus de 25 ans dans le domaine et a contribué, pour des équipes académiques comme pour des start-ups, à la réalisation de plus de 30 programmes de recherche sur différents types de MTI : thérapie génique in vivo ou ex vivo, thérapie cellulaire, ingénierie tissulaire… Il est actuellement Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris. Le centre MEARY est une plateforme de l’Assistance Publique – Hôpitaux de Paris (AP-HP), dédiée à la fabrication de médicament de thérapie innovante expérimentaux. Laboratoire membre de l’ISCT, il est autorisé par l’ANSM et dispose d’un certificat GMP. A ce titre Jean-Roch Fabreguettes est impliqué dans le développement clinique et la fabrication de nombreux MTI : CAR-T cells, lymphocytes T régulateurs, cellules stromales mésenchymateuses…

Précédemment, Jean-Roch Fabreguettes a été expert Qualité (CMC) auprès de l’ANSM durant 9 ans et a conseillé différentes sociétés de biotechnologies. Il est un intervenant régulier pour l’Université Paris Cité et un membre actif de l’ISCT et de réseaux nationaux et internationaux sur les MTI (UNI-TC, Join4ATMP).